Hematology

ASH 2016: A Clinical Overview of JAK Inhibitor Therapeutics for the Management of Patients with Polycythemia Vera
http://academiccme.com/wp-content/uploads/2017/02/ASH-Image--wpcf_80x80.jpg
This CME program will highlight recent scientific advances in the treatment and management of patients with polycythemia vera (PV) presented at the American Society of Hematology 58th Annual Meeting & Exposition in San Diego, California…
Downloadable Transcript , Post Conference Review and Analysis
EHA 2016: New Therapeutic Strategies for the Management of Patients with Relapsed-Refractory Multiple Myeloma
http://academiccme.com/wp-content/uploads/2016/08/910640-125-x-125-wpcf_80x80.jpg
This CME program will cover data on new therapeutic strategies for the management of patients with relapsed-refractory multiple myeloma that were presented at the European Hematology Association 2016 Annual Congress…
Meeting Reporter, Downloadable Transcript
Applying Janus Kinase 2 (JAK2) Inhibitors to the Treatment of Chronic Myelofibrosis
http://academiccme.com/wp-content/uploads/2015/06/42_Website-Graphic-wpcf_80x80.png
This unique webcast will be led and developed by a panel of expert physicians who specialize in myelofibrosis. The challenges of clinical practice with regard to appropriate diagnosis, pathophysiology, patient education, improving adherence, and clinical trial data will be presented and discussed…
Maximizing the Therapeutic Potential of Janus Kinase 2 (JAK2) Inhibitors in Patients with Chronic Myelofibrosis
http://academiccme.com/wp-content/uploads/2015/06/27_Website-Graphic-wpcf_80x80.png
A webcast from the live, satellite symposium at ASH 2014 will cover clinical trial data on JAK2 inhibitor therapeutics, and how it has changed the clinical approach to patients with this illness…
Webcast